Groupama Asset Managment Raises Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)

Groupama Asset Managment raised its stake in Denali Therapeutics Inc. (NASDAQ:DNLI) by 41.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 110,207 shares of the company’s stock after acquiring an additional 32,162 shares during the quarter. Groupama Asset Managment owned approximately 0.08% of Denali Therapeutics worth $2,231,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of DNLI. PNC Financial Services Group Inc. grew its position in shares of Denali Therapeutics by 30.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company’s stock valued at $77,000 after acquiring an additional 885 shares during the period. KBC Group NV boosted its position in Denali Therapeutics by 75.8% during the fourth quarter. KBC Group NV now owns 6,334 shares of the company’s stock worth $129,000 after purchasing an additional 2,731 shares in the last quarter. AlphaQuest LLC grew its holdings in Denali Therapeutics by 177.1% in the fourth quarter. AlphaQuest LLC now owns 6,961 shares of the company’s stock valued at $142,000 after purchasing an additional 4,449 shares during the period. E Fund Management Co. Ltd. increased its position in shares of Denali Therapeutics by 32.2% in the fourth quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company’s stock valued at $204,000 after buying an additional 2,436 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in shares of Denali Therapeutics by 128.8% during the 4th quarter. SG Americas Securities LLC now owns 11,003 shares of the company’s stock worth $224,000 after buying an additional 6,195 shares during the period. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Baird R W raised shares of Denali Therapeutics to a “strong-buy” rating in a report on Tuesday, January 7th. Stifel Nicolaus raised shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a research note on Monday, December 16th. Morgan Stanley began coverage on shares of Denali Therapeutics in a research note on Friday, March 7th. They issued an “overweight” rating and a $33.00 price target on the stock. JPMorgan Chase & Co. reduced their target price on Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating for the company in a report on Tuesday, January 7th. Finally, B. Riley reaffirmed a “buy” rating and issued a $35.00 price target (down from $38.00) on shares of Denali Therapeutics in a research note on Wednesday, March 5th. Two analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Denali Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $37.20.

Insiders Place Their Bets

In other Denali Therapeutics news, CEO Ryan J. Watts sold 29,266 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $20.22, for a total transaction of $591,758.52. Following the transaction, the chief executive officer now directly owns 260,721 shares in the company, valued at $5,271,778.62. This represents a 10.09 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Steve E. Krognes sold 3,339 shares of the firm’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $20.81, for a total value of $69,484.59. Following the transaction, the director now owns 25,757 shares of the company’s stock, valued at approximately $536,003.17. This represents a 11.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 44,860 shares of company stock valued at $909,039 over the last 90 days. 7.90% of the stock is owned by company insiders.

Denali Therapeutics Stock Performance

DNLI stock opened at $13.74 on Thursday. Denali Therapeutics Inc. has a one year low of $12.05 and a one year high of $33.33. The firm has a market cap of $2.00 billion, a PE ratio of -4.98 and a beta of 1.58. The firm’s 50 day moving average price is $18.48 and its 200-day moving average price is $22.91.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.08. Equities research analysts predict that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.